FDA — authorised 2 November 1951
- Application: NDA008126
- Marketing authorisation holder: PHARMACIA AND UPJOHN
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Conventional glucocortidois in United States
FDA authorised Conventional glucocortidois on 2 November 1951
Marketing authorisations
FDA — authorised 3 January 1972
- Application: ANDA080630
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 13 June 1972
- Application: ANDA080776
- Marketing authorisation holder: HIKMA INTL PHARMS
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 9 July 1973
- Application: ANDA083536
- Marketing authorisation holder: IVAX SUB TEVA PHARMS
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 31 August 1973
- Application: ANDA083471
- Marketing authorisation holder: BARR
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 17 October 1974
- Application: ANDA080694
- Marketing authorisation holder: CHARTWELL MOLECULAR
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 22 January 1975
- Application: ANDA084246
- Marketing authorisation holder: EVERYLIFE
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 23 February 1977
- Application: NDA009458
- Marketing authorisation holder: IMPAX LABS
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 7 March 1978
- Application: ANDA085677
- Marketing authorisation holder: WATSON LABS
- Local brand name: CORTISONE ACETATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 15 May 1978
- Application: ANDA085884
- Marketing authorisation holder: WATSON LABS
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA083147
- Marketing authorisation holder: WATSON LABS
- Local brand name: CORTISONE ACETATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA080836
- Marketing authorisation holder: ELKINS SINN
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA080493
- Marketing authorisation holder: PUREPAC PHARM
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA085736
- Marketing authorisation holder: HEATHER
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA080731
- Marketing authorisation holder: INWOOD LABS
- Local brand name: CORTISONE ACETATE
- Indication: TABLET — ORAL
- Status: approved
Other Immunology, Rheumatology, Endocrinology approved in United States
Frequently asked questions
Is Conventional glucocortidois approved in United States?
Yes. FDA authorised it on 2 November 1951; FDA authorised it on 3 January 1972; FDA authorised it on 13 June 1972.
Who is the marketing authorisation holder for Conventional glucocortidois in United States?
PHARMACIA AND UPJOHN holds the US marketing authorisation.